Literature DB >> 17937678

Clonality analysis of lymphoproliferative disorders in patients with Sjögren's syndrome.

L Dong1, Y Masaki, T Takegami, Z-X Jin, C-R Huang, T Fukushima, T Sawaki, T Kawanami, T Saeki, K Kitagawa, S Sugai, T Okazaki, Y Hirose, H Umehara.   

Abstract

The aim of this study was to clarify the nature of the clonal lymphocyte infiltration in Sjögren's syndrome (SS) patients associated with lymphoproliferative disorders. We examined B cell clonality in lymphoproliferative tissues from six primary SS patients associated with lymphoproliferative disorders or lymphoma by cloning and sequencing of the gene rearrangement of the immunoglobulin heavy chain complementarity determining region 3 (IgVH-CDR3). Three patients with sequential observation showed progressional clonal expansion with the presence of the same subclone in different tissues during the course of disease. Among them, one patient developed mucosa-associated lymphoid tissue (MALT) lymphoma in glandular parotid. The other three SS patients concomitant with malignant B cells lymphomas showed different clonal expansion of B cells between nodal sites and salivary glands. The cloanality analysis indicated that monoclonal B cell population could spread from one glandular site to another site during the course of SS, suggesting that the malignant clone may arise from the general abnormal microenvironment, not restricted to the glandular tissue, in some SS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937678      PMCID: PMC2219355          DOI: 10.1111/j.1365-2249.2007.03486.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Simultaneous phenotypically distinct but clonally identical mucosa-associated lymphoid tissue and follicular lymphoma in a patient with Sjögren's syndrome.

Authors:  A Aiello; M Q Du; T C Diss; H Z Peng; F Pezzella; D Papini; R Giardini; S Pilotti; L X Pan; P G Isaacson
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

Review 2.  Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis.

Authors:  X Mariette
Journal:  Leuk Lymphoma       Date:  1999-03

3.  Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome.

Authors:  S Gellrich; S Rutz; A Borkowski; S Golembowski; E Gromnica-Ihle; W Sterry; S Jahn
Journal:  Arthritis Rheum       Date:  1999-02

Review 4.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 5.  Shattuck lecture: Diversity of the immune repertoire and immunoregulation.

Authors:  Robert S Schwartz
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

6.  Coexistence of different B-cell clones in consecutive lesions of low-grade MALT lymphoma of the salivary gland in Sjögren's disease.

Authors:  J Lasota; M M Miettinen
Journal:  Mod Pathol       Date:  1997-09       Impact factor: 7.842

7.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

Authors:  Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

8.  Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions.

Authors:  D W Bahler; S H Swerdlow
Journal:  Blood       Date:  1998-03-15       Impact factor: 22.113

9.  Variable region genes of human monoclonal autoantibodies to histones H2A and H2B from a systemic lupus erythematosus patient.

Authors:  Yong Soon Kwon; Junho Chung; Gyu Tae Shin; Soo Young Lee; Young-Ju Jang
Journal:  Mol Immunol       Date:  2005-02       Impact factor: 4.407

10.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.

Authors:  Richard J Bende; Wilhelmina M Aarts; Robert G Riedl; Daphne de Jong; Steven T Pals; Carel J M van Noesel
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

View more
  5 in total

Review 1.  Malleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

2.  Polymerase chain reaction (PCR) detection of B cell clonality in Sjögren's syndrome patients: a diagnostic tool of clonal expansion.

Authors:  L M Guzmán; D Castillo; S O Aguilera
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

3.  Increased expression of ganglioside GM1 in peripheral CD4+ T cells correlates soluble form of CD30 in Systemic Lupus Erythematosus patients.

Authors:  Lingli Dong; Shaoxian Hu; Fang Chen; Xiaomei Lei; Wei Tu; Yikai Yu; Liu Yang; Wei Sun; Takuro Yamaguchi; Yasufumi Masaki; Hisanori Umehara
Journal:  J Biomed Biotechnol       Date:  2010-06-30

4.  Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome.

Authors:  Lingli Dong; Yu Chen; Yasufumi Masaki; Toshiro Okazaki; Hisanori Umehara
Journal:  Curr Immunol Rev       Date:  2013-02

5.  Development of a low grade lymphoma in the mastoid bone in a patient with atypical Cogan's syndrome: A case report.

Authors:  Chris Kalogeropoulos; Dimitrios Karachalios; George Pentheroudakis; Aikaterini Tsikou-Papafrangou; Lydia Abou-Asabeh; Maria Argyropoulou; Alexandros Drosos; Nicholas Pavlidis
Journal:  J Adv Res       Date:  2014-05-16       Impact factor: 10.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.